<?xml version="1.0" encoding="UTF-8"?>
<fig id="F2" position="float">
 <label>Figure 2</label>
 <caption>
  <p>Remarkable increase in HLA class II-expressing cells after myeloablative (MA) allogeneic stem cell transplantation (alloSCT). Calculated dermal area counts with medians are depicted. No increase in HLA class II-expressing cells 
   <bold>(A)</bold> or T-cells 
   <bold>(B)</bold> was observed after autoSCT. Also, no increase in HLA class II-expressing cells 
   <bold>(C)</bold> or T-cells 
   <bold>(D)</bold> was observed after non-myeloablative (NMA) alloSCT. In contrast, following MA, alloSCT there was a significant increase in HLA class II-expressing cells after 12 and 24 weeks compared to 
   <italic>T</italic> = 0 (Kruskal–Wallis test 
   <italic>p</italic> = 0.020 and 
   <italic>post hoc</italic> Mann–Whitney 
   <italic>U</italic>-test 
   <italic>p</italic> = 0.03 and 0.008) 
   <bold>(E)</bold> and a non-significant increase in T-cells after 24 weeks (Kruskal–Wallis test 
   <italic>p</italic> = 0.12) 
   <bold>(F)</bold>. 
   <bold>(G–I)</bold> Results of fluorescence microscopy of illustrative examples showing HLA class II- and CD3-expressing cells 24 weeks after autologous 
   <bold>(G)</bold>, NMA 
   <bold>(H)</bold>, or MA 
   <bold>(I)</bold> transplantation. White line demarks the border between dermis and epidermis.
  </p>
 </caption>
 <graphic xlink:href="fimmu-09-00331-g002" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
